Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of rExenatide-4 in Chinese T2DM
NCT01342042Phase 2Unknown
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Mar 2011
- Primary completion
- Dec 2011
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of exenatide in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoint: Change in Glycated Hemoglobin at 12 weeks. Status: unknown.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01342042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01342042.